Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03667326 · ClinicalTrials.gov registry record · Phase 2
Postpartum Low-Dose Aspirin and Preeclampsia
A Phase 2 study of Preeclampsia Postpartum, sponsored by Columbia University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT03667326 is a Phase 2 study of Preeclampsia Postpartum that is actively recruiting participants, run by Columbia University. The registered enrollment target is 100 participants, above the 62-participant average among 8 other Preeclampsia Postpartum trials with a reported enrollment target (61% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03667326, a Phase 2 study of Preeclampsia Postpartum, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to find out whether women with severe preeclampsia taking low-dose aspirin (LDA) for 3 weeks post-delivery will experience an improvement in endothelial function (measured as flow-mediated dilation - FMD) and severity of disease, as the effects of preeclampsia can persist postpartum. Women diagnosed with severe preeclampsia prior to delivery will be enrolled and randomized to receive either low-dose aspirin (81mg) or placebo to take daily for up to 3 weeks post-delivery. Exploratory objective includes healthy control postpartum patients without preeclampsia and not on LDA during pregnancy or postpartum in comparison with the primary study population affected by preeclampsia with severe features.
Conditions Studied
Interventions
- DRUG Aspirin tablet
- DRUG Placebo oral capsule
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-07-22 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03667326
The ClinicalTrials.gov registry entry for NCT03667326 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 62-participant average among 8 other Preeclampsia Postpartum trials with a reported enrollment target (61% higher). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Preeclampsia Postpartum appearing as the primary indexed condition, and to 2 interventions - of which Aspirin tablet is the first listed.
NCT03667326 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03667326 about?
NCT03667326 is a clinical study titled "Postpartum Low-Dose Aspirin and Preeclampsia". The purpose of this research study is to find out whether women with severe preeclampsia taking low-dose aspirin (LDA) for 3 weeks post-delivery will experience an improvement in endothelial function (measured as flow-mediated dilation - FMD) and severity of disease, as the effects of preeclampsia c...
What is the current status of trial NCT03667326?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2019-07-22. Estimated completion is 2026-12.
What conditions does trial NCT03667326 study?
This clinical trial studies the following conditions: Preeclampsia Postpartum.
What interventions are being tested in trial NCT03667326?
The interventions under investigation include: Aspirin tablet (DRUG), Placebo oral capsule (DRUG).
Who is sponsoring clinical trial NCT03667326?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03667326 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preeclampsia Postpartum
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Aspirin for Postpartum Patients With Preeclampsia
RECRUITING · Phase 2
-
Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia
RECRUITING · Early Phase 1
-
Aspirin and Preeclampsia
RECRUITING · Phase 4
-
Vascular Effects of High-Salt After Preeclampsia
RECRUITING · Early Phase 1
-
Preeclampsia Educational Program Study (PrEPS)
ACTIVE NOT RECRUITING · NA
-
MR and Inflammation After Preeclampsia
ACTIVE NOT RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.